Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina Inc.

www.illumina.com

Latest From Illumina Inc.

Thermo Fisher VP Wants More IVD Firms Involved In FDA's Manufacturing Maturity Program (Even Though His Company Isn't)

Peter Shearstone, VP of global quality assurance and regulatory affairs at in vitro diagnostic test-maker Thermo Fisher Scientific, is dismayed that only two IVD manufacturers are playing in the US FDA's Case for Quality Voluntary Improvement Program to measure manufacturing maturity and quality – and his firm isn't one of them. "Part of my challenge is moving my company toward proactivity, and if [CFQ VIP] can help do that, then I'd be hypocritical if I didn't embrace it," he says.

FDA Manufacturing

Device Week, 2 July 2019: What Are The Prospects For Medtech Innovation In A Post-Brexit UK?

It may often seem like Brexit is the only story in town in the UK, but within health care and medtech a lot of system transformation and future planning for access to medtech innovation is underway, as this installment of Medtech Insight's Device Week podcast with Ashley Yeo and Amanda Maxwell underlines.

Device Week United Kingdom

UK Plugs Into ‘Golden Period’ For Medtech Innovation

The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.

United Kingdom Market Access

Asia Executives On The Move: New Daiichi CEO, WuXi CMO

The coming of spring has seen the announcement of multiple executive moves in the Asia Pacific region, including a new CEO at Japan's Daiichi Sankyo, while WuXi Apptec and llumina have also made new appointments. Other personnel changes also take place at Shionogi Healthcare and the top of Japan's main regulatory agency.

Appointments China
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Illumina Inc.
  • Senior Management
  • Francis deSouza, Pres. & CEO
    Sam Samad, CFO
    Mark Van Oene, SVP, Chief Commercial Officer
    Garrett Hampton, PhD, EVP, Clinical Genomics
    Omead Ostadan, EVP, Products & Ops
    Mark Stapley, EVP, Strategy & Corp Dev
    Mostafa Ronaghi, PhD, SVP, CTO
  • Contact Info
  • Illumina Inc.
    Phone: (858) 202-4500
    5200 Illumina Way
    San Diego, CA 92122
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register